SynAct Pharma AB (SYNACT.ST)
SEK 9.69
(0.36%)
SEK 9.69
(0.36%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -224.49 Million SEK | -112.38% |
| 2022 | -105.7 Million SEK | -37.82% |
| 2021 | -76.69 Million SEK | -145.16% |
| 2020 | -31.28 Million SEK | -26.14% |
| 2019 | -24.8 Million SEK | 12.64% |
| 2018 | -28.39 Million SEK | -56.06% |
| 2017 | -18.19 Million SEK | -7.18% |
| 2016 | -16.97 Million SEK | -3488.38% |
| 2015 | -473 Thousand SEK | 5.59% |
| 2014 | -501 Thousand SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -25.65 Million SEK | -55.43% |
| 2024 Q2 | -19.03 Million SEK | 25.83% |
| 2024 Q3 | -24.26 Million SEK | -27.49% |
| 2023 Q2 | -43.49 Million SEK | 25.33% |
| 2023 Q4 | -16.5 Million SEK | 47.91% |
| 2023 Q3 | -31.69 Million SEK | 27.14% |
| 2023 FY | -149.88 Million SEK | -41.79% |
| 2023 Q1 | -58.24 Million SEK | -90.83% |
| 2022 Q2 | -26.41 Million SEK | -18.3% |
| 2022 Q4 | -30.52 Million SEK | -15.35% |
| 2022 FY | -105.7 Million SEK | -37.82% |
| 2022 Q1 | -22.33 Million SEK | 14.62% |
| 2022 Q3 | -26.46 Million SEK | -0.17% |
| 2021 Q4 | -26.15 Million SEK | -25.22% |
| 2021 FY | -76.69 Million SEK | -145.16% |
| 2021 Q3 | -20.88 Million SEK | -33.85% |
| 2021 Q2 | -15.6 Million SEK | -10.99% |
| 2021 Q1 | -14.05 Million SEK | -35.75% |
| 2020 Q3 | -8.98 Million SEK | -51.88% |
| 2020 Q4 | -10.35 Million SEK | -15.26% |
| 2020 FY | -31.28 Million SEK | -26.14% |
| 2020 Q1 | -5.99 Million SEK | 32.31% |
| 2020 Q2 | -5.91 Million SEK | 1.4% |
| 2019 Q2 | -6.48 Million SEK | -26.33% |
| 2019 Q4 | -8.86 Million SEK | -105.86% |
| 2019 FY | -24.8 Million SEK | 12.64% |
| 2019 Q1 | -5.13 Million SEK | 32.07% |
| 2019 Q3 | -4.3 Million SEK | 33.64% |
| 2018 Q3 | -7.4 Million SEK | 25.32% |
| 2018 Q4 | -7.56 Million SEK | -2.06% |
| 2018 FY | -28.39 Million SEK | -56.06% |
| 2018 Q2 | -9.92 Million SEK | -183.34% |
| 2018 Q1 | -3.5 Million SEK | 52.8% |
| 2017 FY | -18.19 Million SEK | -7.18% |
| 2017 Q1 | -3.38 Million SEK | 63.61% |
| 2017 Q4 | -7.41 Million SEK | -243.68% |
| 2017 Q3 | -2.15 Million SEK | 58.72% |
| 2017 Q2 | -5.22 Million SEK | -54.38% |
| 2016 Q2 | -5.56 Million SEK | 0.0% |
| 2016 Q3 | -2.08 Million SEK | 62.6% |
| 2016 Q4 | -9.3 Million SEK | -346.84% |
| 2016 FY | -16.97 Million SEK | -3488.38% |
| 2015 FY | -473 Thousand SEK | 5.59% |
| 2014 FY | -501 Thousand SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -248.98 Million SEK | 9.835% |
| Ziccum AB (publ) | -21.56 Million SEK | -941.262% |
| Modus Therapeutics Holding AB (publ) | -16.4 Million SEK | -1268.795% |
| BioArctic AB (publ) | 252.64 Million SEK | 188.86% |
| Sprint Bioscience AB (publ) | -845 Thousand SEK | -26467.574% |
| Mendus AB (publ) | -100.65 Million SEK | -123.046% |
| Genovis AB (publ.) | 54.22 Million SEK | 514.016% |
| Intervacc AB (publ) | -93.57 Million SEK | -139.9% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -15.51 Million SEK | -1347.241% |
| Active Biotech AB (publ) | -46.48 Million SEK | -382.953% |
| Magle Chemoswed Holding AB (publ) | 18 Million SEK | 1346.577% |
| Bio-Works Technologies AB (publ) | -55.41 Million SEK | -305.103% |
| Aptahem AB (publ) | -10.1 Million SEK | -2121.686% |
| Vicore Pharma Holding AB (publ) | -321.5 Million SEK | 30.174% |
| Kancera AB (publ) | -65.04 Million SEK | -245.155% |
| Infant Bacterial Therapeutics AB (publ) | -134.61 Million SEK | -66.766% |
| Fluicell AB (publ) | -26.87 Million SEK | -735.21% |
| Saniona AB (publ) | -81.06 Million SEK | -176.933% |
| Lipigon Pharmaceuticals AB (publ) | -12.37 Million SEK | -1714.696% |
| Biovica International AB (publ) | -126.07 Million SEK | -78.068% |
| Spago Nanomedical AB (publ) | -42.5 Million SEK | -428.164% |
| AcouSort AB (publ) | -17.48 Million SEK | -1183.788% |
| Xintela AB (publ) | -57.23 Million SEK | -292.215% |
| Abliva AB (publ) | -96.54 Million SEK | -132.523% |
| Egetis Therapeutics AB (publ) | -324.8 Million SEK | 30.882% |
| Karolinska Development AB (publ) | -3.5 Million SEK | -6305.021% |
| OncoZenge AB (publ) | -15.9 Million SEK | -1311.747% |
| Amniotics AB (publ) | -29.07 Million SEK | -672.18% |
| 2cureX AB (publ) | -36.36 Million SEK | -517.375% |
| CombiGene AB (publ) | -36.3 Million SEK | -518.358% |
| Asarina Pharma AB (publ) | -14.64 Million SEK | -1433.443% |
| Calliditas Therapeutics AB (publ) | -384.39 Million SEK | 41.598% |
| Camurus AB (publ) | 532.35 Million SEK | 142.17% |
| Corline Biomedical AB | -1.78 Million SEK | -12455.705% |
| IRLAB Therapeutics AB (publ) | -180.76 Million SEK | -24.192% |
| Isofol Medical AB (publ) | -41.68 Million SEK | -438.579% |
| I-Tech AB | 24.43 Million SEK | 1018.748% |
| Hansa Biopharma AB (publ) | -788.49 Million SEK | 71.529% |
| Cyxone AB (publ) | -21.66 Million SEK | -936.406% |
| ExpreS2ion Biotech Holding AB (publ) | -105.96 Million SEK | -111.859% |
| Biosergen AB | -27.26 Million SEK | -723.385% |
| Cantargia AB (publ) | -290.01 Million SEK | 22.592% |
| NextCell Pharma AB | -43.17 Million SEK | -420.002% |
| Xspray Pharma AB (publ) | -180.76 Million SEK | -24.192% |
| Elicera Therapeutics AB (publ) | -17.09 Million SEK | -1213.128% |
| Nanologica AB (publ) | -69.96 Million SEK | -220.878% |
| Annexin Pharmaceuticals AB (publ) | -44.17 Million SEK | -408.185% |
| Stayble Therapeutics AB (publ) | -23.95 Million SEK | -837.186% |
| LIDDS AB (publ) | -40.67 Million SEK | -451.94% |
| Lipum AB (publ) | -37.25 Million SEK | -502.609% |
| BioInvent International AB (publ) | -369.94 Million SEK | 39.316% |
| Alzinova AB (publ) | -16.52 Million SEK | -1258.77% |
| Oncopeptides AB (publ) | -253.44 Million SEK | 11.423% |
| Pila Pharma AB (publ) | -6.39 Million SEK | -3411.454% |
| Guard Therapeutics International AB (publ) | -115.07 Million SEK | -95.09% |
| Scandinavian ChemoTech AB (publ) | -20.13 Million SEK | -1014.733% |
| Simris Alg AB (publ) | -36.63 Million SEK | -512.791% |
| Diamyd Medical AB (publ) | -146.56 Million SEK | -53.17% |
| Xbrane Biopharma AB (publ) | -310.42 Million SEK | 27.681% |
| Ascelia Pharma AB (publ) | -110.91 Million SEK | -102.405% |
| Diagonal Bio AB (publ) | -11.56 Million SEK | -1840.999% |